Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.5692 USD
−28.54 M USD
0.00 USD
44.48 M
About ESSA Pharma Inc.
Sector
Industry
CEO
David R. Parkinson
Website
Headquarters
Vancouver
Founded
2009
ISIN
CA29668H7085
FIGI
BBG0088NJ8D1
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
Related stocks
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of EPIX is 0.2010 USD — it has increased by 0.40% in the past 24 hours. Watch ESSA Pharma Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ESSA Pharma Inc. stocks are traded under the ticker EPIX.
EPIX stock has fallen by −5.68% compared to the previous week, the month change is a −18.95% fall, over the last year ESSA Pharma Inc. has showed a −96.70% decrease.
EPIX reached its all-time high on Jun 22, 2015 with the price of 245.0000 USD, and its all-time low was 0.1800 USD and was reached on Sep 24, 2025. View more price dynamics on EPIX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
EPIX stock is 5.24% volatile and has beta coefficient of 1.39. Track ESSA Pharma Inc. stock price on the chart and check out the list of the most volatile stocks — is ESSA Pharma Inc. there?
Today ESSA Pharma Inc. has the market capitalization of 9.51 M, it has decreased by −1.36% over the last week.
Yes, you can track ESSA Pharma Inc. financials in yearly and quarterly reports right on TradingView.
ESSA Pharma Inc. is going to release the next earnings report on Dec 23, 2025. Keep track of upcoming events with our Earnings Calendar.
EPIX earnings for the last quarter are −0.09 USD per share, whereas the estimation was −0.17 USD resulting in a 47.06% surprise. The estimated earnings for the next quarter are −0.16 USD per share. See more details about ESSA Pharma Inc. earnings.
EPIX net income for the last quarter is −4.00 M USD, while the quarter before that showed −6.37 M USD of net income which accounts for 37.20% change. Track more ESSA Pharma Inc. financial stats to get the full picture.
As of Sep 28, 2025, the company has 35 employees. See our rating of the largest employees — is ESSA Pharma Inc. on this list?
Like other stocks, EPIX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ESSA Pharma Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ESSA Pharma Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ESSA Pharma Inc. stock shows the sell signal. See more of ESSA Pharma Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.